Enabling Protein Degradation Drug Discovery

Ian Ratcliffe

Board Member

Ian Ratcliffe founded Stemgent – a stem cell reagent and service company – in 2008 and serves as its Executive Chairman. Stemgent acquired Asterand Plc’s Human Tissue Business in July 2012. Previously Ian was President of Upstate Biotechnology, a leading provider of cell signalling research products and services which was acquired by Serologicals, Corp. in 2004. Ian is also the Chairman of Enzymatics, a manufacturer of molecular biology reagents and a director of Global Cell Solutions, a biotech company commercialising proprietary 3D cell culture technology. Ian is a General Partner with Keswick Ventures and has a degree in Chemical Engineering from the University of Surrey and an MBA from the Darden Graduate School of Business Administration at the University of Virginia.